Tracers / [177Lu]Lu-LW01142

[177Lu]Lu-LW01142

Also written as [Lu-177]Lu-LW01142

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

What it is

Compound class: DOTA-conjugated bombesin(6-14) peptide analog (GRPR-targeted agonist)
Target / mechanism: Gastrin-releasing peptide receptor (GRPR) agonist PMID 40283887
Clinical application: Targeting gastrin-releasing peptide receptor (GRPR)-expressing cancer (prostate cancer, PC-3 tumor model) PMID 40283887
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	custom manifold	HPLC+SPE	24-62% yes	>91%	LW01142	40283887 2025 Pharmaceuticals (Basel) 843–1043 MBq of 177LuCl3 solution was added into a 4 mL glass vial containing 0.7 mL of NaOAc buffer (0.1 M, pH 4.5) and 10 μL precursor solution (1 mM), followed by a 15 min incubation at 95 °C. — The 177Lu-labeled TacsBOMB5, LW01110, LW01142, and AMBA were obtained in 24–62% decay-corrected radiochemical yields

Need this precursor?We can point you to suppliers for [177Lu]Lu-LW01142, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40283887. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.